Biotech upstart adds a failed Merck KGaA drug to the pipeline, mapping new combo approach to MAPK pathway
Can a biotech startup succeed where a big pharma player failed? Day One plans to find out after in-licensing a pair of discards from Merck …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
